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Emergence and spread of drug resistant Neisseria gonorrhoeae is global concern. We evaluated trends of antimicrobial resistance
in Neisseria gonorrhoeae over years 1992–2009 in Pakistan. Resistance rates were compared between years (2007–2009) and
(1992–2006). Antimicrobial susceptibility testing was performed and interpreted according to Clinical Laboratory Standards
Institute (CLSI) criteria using the disk diﬀusion methodology against penicillin, ceftriaxone, tetracycline and oﬂoxacin. Additional
antibiotics tested in 100 strains isolated during 2007–2009, included cefotaxime, cefoxitin, cefuroxime, ceﬁpime, ceftazidime,
ceftizoxime, ceﬁxime, cefpodoxime, spectinomycin and azithromycin. Neisseria gonorrhoeae ATCC 49226 was used as control.
Chi-square for trend analysis was conducted to assess resistance trend over the study period. During study period signiﬁcant
increase in combined resistance to penicillin, tetracycline and oﬂoxacin was observed (P value <0.01). Resistance rates during the
two study period also increased signiﬁcantly (P value <0.01). Ceftriaxone resistance was not observed. None of the isolates were
found to be resistant or with intermediate sensitivity to additional antibiotics. Our ﬁndings suggest that penicillin, ciproﬂoxacin,
tetracycline should not be used in the empirical treatment of gonorrhea in Pakistan. Ceftriaxone and ceﬁxime should be the ﬁrst
line therapy; however periodic MICs should be determined to identify emergence of strains with reduced susceptibility.
1.Introduction
Gonorrhea continues to be a public health problem with the
emergence of multidrug resistant strains [1]. Accurate diag-
nosiswitheﬀectivetreatmenttopreventfurthertransmission
is one of the essential elements for control of gonococcal
infections [2]. Treatment strategies should be devised to
utilize appropriate and preferably single-dose therapy that
could be conveniently administered at the time of diagnosis
[3]. Surveillance of Neisseria gonorrhoeae antimicrobial resis-
tanceiscrucialinguidingempiricaltherapyinanyindividual
setting as resistance may vary in diﬀerent countries [4].
Neisseria gonorrhoeae i n f e c t i o n sh a v eb e e nr e p o rt e df r o m
Pakistan as a cause of sexually transmitted infections, but
unfortunately national surveillance data is not available to
assess its prevalence or antimicrobial resistance [5, 6]. Due to
limitedresourcesandlackoftrainedtechnologistandmicro-
biologists, most of the laboratories do not report Neisseria
gonorrhoeae.Therefore,existingantimicrobialresistancedata
from the country is limited and mainly laboratory based.
Previously high resistance rates to penicillin, tetracycline,
and quinolone have already been reported from the country
[7, 8]. Thus ongoing surveillance of resistance is important
considering the public health importance of gonococcal
infections. In this study, we have evaluated antimicrobial
resistance in Neisseria gonorrhoeae for the years (2007–
2009) and compared it with previously reported data (1992–
2006).Additionally,100strainsfrom2007–2009werefurther
analyzed for additional treatment options.
2.MaterialsandMethods
ThisstudywasconductedintheclinicallaboratoryoftheAga
Khan University Hospital (AKUH), Karachi, Pakistan. The
AKUHlaboratoryisaccreditedwiththeJointCommissionof2 Journal of Tropical Medicine
InternationalAccreditation(JCIA)androutinelyparticipates
in the external quality assurance programme of College
of American Pathologists (CAP). The laboratory has a
well-established national specimen collection network with
more than 175 collection units located in major cities
and towns across the country. Specimens are requested by
physicians as per their judgment and are processed in the
clinical laboratory based in Karachi. The laboratory data
presented in this study although was not collected through a
programmed survey, but represents strains prevalent across
the country.
2.1. Collection of Isolates. All Neisseria gonorrhoeae strains
isolated from clinical samples were evaluated for their
susceptibility pattern. Information regarding the age, sex,
year of isolation, and specimen type was retrieved from the
computerized database.
2.2. Laboratory Methods. Neisseria gonorrhoeae was isolated
and identiﬁed using standard microbiological procedure [9].
All isolates in 2007–2009 were saved in glycerol phosphate
broth and stored at −80◦C.
2.3. Antimicrobial Susceptibility Testing. During the study
period, antimicrobial susceptibility testing was performed
and interpreted according to Clinical Laboratory Standards
Institute (CLSI) criteria using the disk diﬀusion methodol-
ogy [10]. All isolates were tested against penicillin (10µg),
ceftriaxone (30µg), tetracycline (30µg), and oﬂoxacin (5µg)
(Oxoid) on GC agar base and 1% deﬁned growth sup-
plement. Minimum inhibitory concentration (MIC) of
oﬂoxacin was determined in strains isolated during 2007–
2009 by the E-test method (AB biodisk, Sweden) on GC
agar base and 1% deﬁned growth supplement. MIC with E
test was performed as speciﬁed by the manufacturer. Addi-
tional antibiotics tested in selected strains isolated during
2007–2009 included cefotaxime (30µg), cefoxitin (30µg),
cefuroxime (30µg), ceﬁpime (30µg), ceftazidime (30µg),
ceftizoxime (30µg), ceﬁxime (30µg), cefpodoxime (30µg)
spectinomycin (100µg), and azithromycin (15µg) (Oxoid).
The antimicrobial susceptibility of all these antibiotics was
interpreted according to CLSI criteria except azithromycin
that was interpreted using British Society of Antimicrobial
Chemotherapy (BSAC) methods for antimicrobial suscepti-
bility testing [11]. Neisseria gonorrhoeae ATCC 49226 was
used as control for disc diﬀusion and MIC testing. Beta-
lactamase production was checked using nitroceﬁn reagent.
Strains resistant to penicillin, tetracycline, and oﬂoxacin
were categorized as having combined resistance to penicillin,
tetracycline, and oﬂoxacin.
2.4. Data Management and Statistical Analysis. Data ex-
tracted from the computerized information system were
transferred to the statistical software SPSS version 14.0.
Frequencies with percentages were computed for each year.
Chi-square for trend analysis was also conducted to assess
resistance trend over the study period. A P-value of less than
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Figure 1: Comparison of resistance in Neisseria gonorrhoeae strains
during years 1992–2006 and 2007–2009. There is a signiﬁcant
increase (P-value <0.01) in resistance to penicillin, tetracycline,
oﬂoxacin,andcombinedresistancetoall3antibioticsoverthesetwo
periods. n is the total number of strains for that particular period.
3. Results
A total of 804 Neisseria gonorrhoeae strains were isolated and
identiﬁed during 1992–2009. Of which 82% isolates were
from males and 18% were from females. Majority (93%)
of organisms were isolated from urethral, high vaginal, and
cervical swabs, (6%) were from pus aspirates, and (1%) were
from eye swabs, blood, and urine.
Duringthestudyperiod,anincreasingtrendofresistance
was observed against penicillin, tetracycline, and oﬂoxacin
(P-value for trends <0.01) (Table 1). N. gonorrhoeae strains
with combined resistance to penicillin, tetracycline, and
oﬂoxacin increased from (0%) in 1992 to (70.8%) in 2009
(P-value for trends <0.01). Table 2 shows N. gonorrhoeae
strains showing intermediate susceptibility during the study
period. No resistant strains to ceftriaxone were picked up
by the disk diﬀusion method during the 15-year period.
Comparison of resistance rates during years 1992–2006
and 2007–2009 revealed signiﬁcantly increased resistance
between the two periods (Figure 1).
Susceptibility to cefotaxime, cefoxitin, cefuroxime, ceﬁp-
ime, ceftazidime, ceftizoxime, ceﬁxime, cefpodoxime, specti-
nomycin, and azithromycin was determined in 100 isolates.
Resistanceagainsttheabove-mentioned agentswasnotiden-
tiﬁed, and 100% of the tested isolates were found susceptible.
4. Discussion
The results of our study demonstrated increasing trend of
resistance in N. gonorrhoeae against penicillin, tetracycline,
and oﬂoxacin in Pakistan. The resistance rates reported
in this study against ﬁrst-line drugs markedly exceed the
World Health Organization cutoﬀ of 5%, precluding their
use for the empirical therapy in gonococcal infections
[12]. Accurate information on antimicrobial susceptibility of
prevalent N. gonorrhoeae is, thus, essential for the treatment
and control of this disease. Keeping in view the current
scenario in Pakistan and absence of a national guideline
for treatment of gonococcal infections, the selection ofJournal of Tropical Medicine 3
Table 1: Antimicrobial resistance trends in Neisseria gonorrhoeae strains over the years 1992–2009 showing signiﬁcant increase in resistance
to penicillin, tetracycline, and oﬂoxacin. There is also signiﬁcant increase in combined resistance to all 3 antibiotics. n is the total number of
resistance strains for that particular year. Percentage is shown in parenthesis (%).
Years Total number of strains CRO OFX P TE MDR
n (%) n (%) n (%) n (%) n (%)
1992 15 0 0 1 (7.7) 0 0
1993 11 0 0 0 0 0
1994 16 0 0 4 (25) 0 0
1995 28 0 0 1 (3.6) 0 0
1996 20 0 0 0 0 0
1997 25 0 0 8 (32) 5 (20) 0
1998 26 0 0 3 (11.5) 1 (3.8) 0
1999 33 0 6 (28.8) 6 (19.4) 3 (9.7) 0
2000 25 0 6 (24) 2 (8) 0 0
2001 26 0 6 (23.1) 5 (19.2) 1 (3.8) 0
2002 19 0 8 (42.1) 1 (5.3) 2 (10.5) 0
2003 51 0 37 (72.5) 15 (29.4) 13 (25.5) 7 (13.7)
2004 56 0 47 (83.9) 29 (51.8) 26 (46.4) 17 (30.4)
2005 61 0 48 (78.7) 18 (29.5) 36 (59) 13 (21.3)
2006 90 0 71 (78.9) 39 (43.3) 49 (54.4) 25 (27.8)
2007 95 0 79 (83.2) 57 (60) 62 (65.3) 39 (41.1)
2008 116 0 107 (92.2) 94 (81) 93 (80.2) 79 (68.1)
2009 106 0 98 (92.5) 92 (86.8) 82 (77.6) 75 (70.8)
P-value for trends NA <0.01 <0.01 <0.01 <0.01
P: Penicillin; TE: Tetracycline; OFX: Oﬂoxacin; CRO: Ceftriaxone; MDR: strains resistant to penicillin, tetracycline, and oﬂoxacin.
Table 2: Neisseria gonorrhoeae strains with intermediate suscepti-
bility over the study period 1992–2009. n is the total number of
intermediate strains for that particular year. Percentage is shown in
parenthesis (%).
Years n OFX P TE
1992 15 0 1 (7.7) 0
1993 11 0 1 (9.1) 0
1994 16 0 5 (31.3) 3 (23.1)
1995 28 0 9 (32.1) 8 (28.6)
1996 20 0 1 (5.3) 2 (10)
1997 25 0 7 (28) 7 (28)
1998 26 0 3 (11.5) 4 (15.4)
1999 33 1 (4.8) 3 (9.7) 8 (25.8)
2000 25 0 (0) 4 (16) 3 (12)
2001 26 2 (7.7) 2 (7.7) 3 (11.5)
2002 19 1 (5.3) 10 (52.6) 2 (10.5)
2003 51 5 (9.8) 22 (43.1) 6 (11.8)
2004 56 0 (0) 13 (23.2) 3 (5.4)
2005 61 2 (3.3) 36 (59) 5 (8.2)
2006 90 9 (10.1) 42 (46.7) 15 (16.7)
2007 95 4 (4.2) 31 (32.6) 23 (24.2)
2008 116 5 (4.3) 16 (13.8) 17 (14.7)
2009 106 6 (5.7) 12 (11.3) 16 (15.1)
P: Penicillin; TE: Tetracycline; OFX: Oﬂoxacin.
appropriate antibiotics for empirical treatment of gonorrhea
is challenging.
This 10-year analysis clearly showed that the level of
resistance to traditional antibiotics used in the treatment
of gonorrhea continued to increase in local isolates. This
trend follows the global pattern of antibiotic resistance in
N.gonorrhoeaeandleavesthird-generationcephalosporinsas
the recommended antibiotic for its treatment [13]. However
emergence and spread of strains with reduced susceptibility
to ceftriaxone is another emerging issue. Unfortunately,
these strains are simultaneously resistance to multiple drug
classes, including quinolones, macrolides, penicillins, and
tetracyclines [14]. We did not perform ceftriaxone MIC,
required to detect reduced susceptibility, and there is a
possibility to miss their occurrence as the frequency of
MDR strains constitutes a large proportion of our current
N. gonorrhoeae isolates circulating in the community. On
the other hand, treatment failure with ceftriaxone has not
been documented from the country. The best strategy in
this scenario would be periodic determination of ceftriaxone
MICs to detect existence of these strains and close followup
with clinicians to identify treatment failure.
A high quinolone resistance approaching almost 100%
in recent years was demonstrated in local isolates. This
exponential rise in quinolone resistance has also been
reportedfromtheregionandraisesseveralconcerns[15,16].
We had not evaluated the exact reason for this ﬁnding, but
probable reasons could be its continuous use despite higher
rate of resistance and poor disease control in the community.
Increased resistance rates to quinolones have been reported
from the country in other community acquired pathogens
highlighting the overall misuse of quinolones as the major
reason of increased resistance [17, 18].
In view of high resistance to the currently tested antimi-
crobials in our setting, we tested 8 cephalosporins including4 Journal of Tropical Medicine
3 oral options: ceﬁxime, cefpodoxime, and cefuroxime.
The eﬃcacy of ceﬁxime has been shown to be similar to
ceftriaxone [19]. Although cefpodoxime and cefuroxime
have shown a cure rate of more than 95%, their phar-
macodynam-ic parameters are less favorable than those
of ceﬁxime and ceftriaxone [20, 21]. Nevertheless, they
could be used as oral alternatives in the treatment of
uncomplicated gonorrhea in our setting [22]. Cefotaxime,
cefoxitin, cefepime, ceftazidime, and ceftizoxime are the
other single-dose cephalosporins included in the updated
treatment regimens for gonococcal infections by the Centers
for Disease Control and Prevention [23]. Although studies
have reported emergence of resistance to these agents, we
were not able to detect resistance against any of them in this
study.
Local isolates were also uniformly susceptible to specti-
nomycin, which is a good option especially in those patients
who cannot tolerate cephalosporins [24]. The most likely
reason for its consistent susceptibility is its less-frequent use
in the community. Rapid emergence of resistance has been
reported with the wider use of spectinomycin mandating its
rationale use.
Though azithromycin is so far not recommended as
a single agent for the treatment of gonorrhea, it has a
potential role in the management of these infections in
combination with third-generation cephalosporin. We did
not detect resistance to this drug although strains with high
level resistance have emerged as another threat [25, 26].
Although our dataset included samples from all over
Pakistan, sampling limitations prevent us from generalizing
our results to the entire population of the country. However,
it is important to note that only a few laboratories in
the country perform antimicrobial susceptibility testing in
Neisseria gonorrhoeae, and our data is the largest ever
from the country reporting resistance over time. Another
limitation is lack of MICs determination for cephalosporins
withpossibilityofmissingstrainswithreducedsusceptibility.
In conclusion, we recommend that penicillin, ciproﬂox-
acin, and tetracycline should not be used in the empirical
treatment of gonorrhoeae. Ceftriaxone and ceﬁxime should
be the ﬁrst line therapy; however, periodic MICs should be
determined to identify emergence of strains with reduced
susceptibility. Optimized, standardized, and quality assured
antibiotic susceptibility testing needs to be established in
laboratories in Pakistan. Simultaneously prevention strate-
gies should be strengthened to maximize the clinical utility
of these antimicrobials. Such strategies could include the
use of a limited number of treatment regimens and overall
avoiding a general misuse of the remaining yet eﬀective
antibiotics. In addition, a national policy for management of
gonococcal infections should be developed and disseminated
to clinicians in the country.
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